Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

Acute myeloid leukemia (AML) remains challenging to treat and needs more effective treatments. The PI3K/mTOR pathway is involved in cell survival and has been shown to be constitutively active in 50–80% of AML patients. However, targeting the PI3K/mTOR pathway results in activation of the ERK pathwa...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Biochem Pharmacol
Auteurs principaux: Su, Yongwei, Li, Xinyu, Ma, Jun, Zhao, Jianyun, Liu, Shuang, Wang, Guan, Edwards, Holly, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858997/
https://ncbi.nlm.nih.gov/pubmed/29208365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2017.11.022
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires